Title
Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.

Permalink
https://escholarship.org/uc/item/3zj1j8n8

Journal
Neoplasia (New York, N.Y.), 21(1)

ISSN
1522-8002

Authors
Kurhanewicz, John
Vigneron, Daniel B
Ardenkjaer-Larsen, Jan Henrik
et al.

Publication Date
2019

DOI
10.1016/j.neo.2018.09.006

Peer reviewed
Abstract
This white paper discusses prospects for advancing hyperpolarization technology to better understand cancer metabolism, identify current obstacles to HP (hyperpolarized) $^{13}$C magnetic resonance imaging’s (MRI’s)
Introduction

Recent advances in cancer metabolism have generated considerable interest among clinicians. However, the only imaging agent regularly used in the clinic to assess metabolism is the glucose analog [18F] fluorodeoxyglucose (FDG), a positron emission tomography (PET) tracer that reports on local glucose uptake in many cancers, inflammation, and other processes. While FDG PET has been an extremely successful approach, it cannot assess downstream metabolism that is often important to more fully understand cancer. Hyperpolarized magnetic resonance imaging (HP MRI) provides a unique window into metabolic alterations based on its ability to measure molecular transformations of the imaging agent. The method dramatically, although temporarily, increases MRI signal, which allows in vivo imaging of biologically active molecules that was impossible with conventional methods. Dynamic nuclear polarization of 13C-labeled biomolecules (probes) is currently the dominant hyperpolarization process used for preclinical work, and it is the only one that has been translated to patient studies. Due to space limitations, this white paper will focus on dynamic nuclear polarization-based polarization of 13C probes, although there are other methods to generate HP 13C-probes including para-hydrogen and brute force-based approaches, and other nuclear magnetic resonance active nuclei such as [129Xe], [15N], and [31P] have been hyperpolarized.

The potential to diagnose and better characterize cancer biology, predict cancer progression, and monitor early response to treatment using HP MRI was highlighted in the first NIH white paper on this technology in 2011. Since then, a polarizer capable of producing hyperpolarized material for human injection was commercially introduced, and the safety of hyperpolarized [1-13C] pyruvate as a tool for measuring changes in tumor metabolism in patients was demonstrated. This white paper will highlight preclinical advances, technical needs, and early experience with patients and discuss how HP MRI might fill existing needs in current clinical research and practice. Finally, we will examine obstacles to HP MRI’s widespread clinical use and outline a path for clearing them.

The Continuing Need for Animal Models

In addition to providing the only plausible method for testing the feasibility and safety of new HP molecular probes, preclinical animal studies are crucial for refining the methods for their use in specific diseases and for validating quantitative HP measurements of metabolism against tissue assays. Animal studies also provide the opportunity to better understand fundamental aspects of biochemistry and its modification by disease, therapy, nutritional state, and prescribed experimental conditions, which is possible in preclinical models but not in patients. Even if some HP probes prove inappropriate for clinical translation, their use in preclinical studies can still yield information of real clinical value by elucidating the metabolic pathways that novel treatment strategies could target.

HP Pyruvate for Diagnosis, Progression, and Response to Therapy

[1-13C]pyruvate was among the first HP probes introduced and remains the most widely studied in preclinical cancer models because it is easy to polarize, T1 is relatively long, and it occupies a critical branch point central to a number of significant metabolic pathways. Pyruvate is the product of glycolysis, and its major fates include reduction to [1-13C]lactate via the enzyme lactate dehydrogenase (LDH) or oxidative metabolism to acetyl-coA with production of [13C] bicarbonate in the mitochondria. Both processes result in an altered chemical shift that HP MRI is able to image at uniquely high temporal resolution. Although some exceptions have been observed, the majority of preclinical cancer studies using HP pyruvate as a biomarker have shown increased conversion to HP lactate, consistent with the elevated lactate production (Warburg effect) that is an established characteristic of most cancerous cells. This white paper will highlight preclinical advances, technical needs, and early experience with patients and discuss how HP MRI might fill existing needs in current clinical research and practice. Finally, we will examine obstacles to HP MRI’s widespread clinical use and outline a path for clearing them.

widespread clinical use, and provide recommendations for overcoming them. Since the publication of the first NIH white paper on hyperpolarized 13C MRI in 2011, preclinical studies involving [1-13C]pyruvate as well a number of other 13C labeled metabolic substrates have demonstrated this technology’s capacity to provide unique metabolic information. A dose-ranging study of HP [1-13C]pyruvate in patients with prostate cancer established safety and feasibility of this technique. Additional studies are ongoing in prostate, brain, breast, liver, cervical, and ovarian cancer. Technology for generating and delivering hyperpolarized agents has evolved, and new MR data acquisition sequences and improved MRI hardware have been developed. It will be important to continue investigation and development of existing and new probes in animal models. Improved polarization technology, efficient radiofrequency coils, and reliable pulse sequences are all important objectives to enable exploration of the technology in healthy control subjects and patient populations. It will be critical to determine how HP 13C MRI might fill existing needs in current clinical research and practice, and complement existing metabolic imaging modalities. Financial sponsorship and integration of academia, industry, and government efforts will be important factors in translating the technology for clinical research in oncology. This white paper is intended to provide recommendations with this goal in mind.
Elevated transformation of hyperpolarized pyruvate to lactate has been established as a predictor of tumor progression in the transgenic adenocarcinoma of the mouse prostate "model" and genetically engineered pancreatic cancer models, while a similar effect was also seen in longitudinal studies of liver cancer models, alongside increased transamination of pyruvate to alanine. The latter effect has the potential to provide valuable information regarding tumor heterogeneity, with obvious implications for the development of more sensitive and personal treatment. The possibility of acquiring such a combined measurement was demonstrated using copolarized [1-13C]pyruvate and [13C]urea in rats: metabolic alterations were registered via the conversion of pyruvate into 13C bicarbonate, while alterations in perfusion were measured via changes in myocardial signals of pyruvate and urea.

Numerous biologically relevant, potentially polarizable molecules remain unstudied, and new HP probes to detect and assess response to various types of cancer treatment are urgently needed. For example, because MRI of HP pyruvate is unable to differentiate increased lactate production associated with tumor cells from that associated with inflammatory cells, other probes—such as the recently tested HP [6-13C]arginine—are necessary for monitoring response to therapies that target this cell type. In addition, the development of hyperpolarized biomarkers capable of monitoring response to the most promising immunotherapies currently in use, such as checkpoint inhibitors, is a major unmet need which should command immediate preclinical attention. Probes tailored to the innate or designed metabolic characteristics of such cellular therapeutic agents would be extremely valuable for assessing treatment efficacy at a very early stage.

Further Avenues of Preclinical Animal Study

Preclinical animal studies enable investigation of appropriate methods to report HP data or integrate multiple HP measurements, for example, through the development and testing of methods for the true simultaneous measurement of perfusion and metabolism to improve quantitation and facilitate identification of poorly perfused but metabolically active disease that is often highly aggressive and difficult to treat. The possibility of acquiring such a combined measurement was demonstrated using copolarized [1-13C]pyruvate and [13C]urea in rats: metabolic alterations were registered via the conversion of pyruvate into 13C bicarbonate, while alterations in perfusion were measured via changes in myocardial signals of pyruvate and urea.
is particularly suited to this kind of combined measurement. Because ratiometric measurements are potentially subject to bias in the case of differing uptake or relaxation characteristics, preclinical models are critical for validation using histological and invasive techniques that are not practical in human subjects.

In addition to exploring HP technology, preclinical animal studies enable measurements that are not feasible in human subjects for reasons such as invasiveness, toxicity, or the current inability to hyperpolarize substrates in sufficient volume. Studies using genetically engineered and patient-derived xenograft models enable the combined use of PET and HP MRI, as well as the collection of a robust spectrum of supporting in vivo and histological measurements, including metabolite and enzyme profiles as well as histochemical measurements of enzyme heterogeneity, which can both confirm and enhance the data collected via these primary imaging modalities. While the ability to collect such supplementary measurements is undoubtedly crucial to validating the accuracy of primary measurements enabled by HP probes, its ultimate value may lie in the more general expansion of our understanding of the biochemical properties characteristic of specific disorders. For example, HP probes are currently being used to assess the progression of lung and brain injury, yielding valuable insights into the mechanism of injury propagation. While these studies are not directly applicable to imaging human injury using HP agents in the clinic, the information gained will help guide therapeutic approaches that could have significant clinical impact.

**Needs and Future Directions**

There is substantial need for preclinical polarizers capable of achieving high polarization and tailored for producing masses of material suitable for rodent exams. Such a polarizer that is less expensive than a clinical device would dramatically expand preclinical efforts and speed clinical investigations. High levels of polarization increase the signal-to-noise ratio and potentially open up previously undetectable biological pathways for study. High levels of polarization may also allow a reduction in the injected probe concentration. HP probes are injected at physiologic or supraphysiologic doses, and preclinical studies investigating the extent to which physiologic concentrations of HP probe might perturb in vivo metabolism relative to a tracer approach like PET are key to the proper interpretation of HP MRI findings. As previous work has demonstrated, this increased polarization is most easily achieved by employing higher magnetic fields and lower temperatures during the polarization process.

Optimized pulse sequences can also be used to preserve the magnetization of specific hyperpolarized substrates while enhancing the detection of products. Since the lack of standardized techniques remains an obstacle to the growth of HP MRI as a field of study, this represents a potential opportunity for the research community to collaborate with small imaging system manufacturers on the creation of standard imaging sequences and basic processing protocols, thereby possibly expanding the use of HP MRI techniques beyond labs with a strong MRI physics focus. Other beneficial technical improvements would include the development of a less complex user interface, as well as a more direct, rapid mechanism for the delivery of polarized agents into the animal or cell or tissue culture bioreactor.

The development and optimization of new hyperpolarized molecular probes, and preclinical studies that accurately recapitulate important aspects of human disorders—whether using primary cells and tissues, genetically engineered, patient-derived xenograft, or other models—continue to be of great value. Robust mechanistic validation linking hyperpolarized metabolic observations to established biological events are also essential to establish the value of hyperpolarized imaging approaches and their potential limitations. Significant effort is currently under way—and should be further encouraged—to explore the use of HP imaging biomarkers to inform on a variety of disease conditions and therapeutic strategies and to integrate this unique new information to positively affect outcome. The combined use of targeted therapeutic approaches and HP MRI in these models will provide a framework for accessing HP biomarkers of treatment response for clinical translation. It is also important to conduct more studies to validate the use of HP MRI in combination with other imaging modalities such as PET, as was recently done during a single imaging session in a canine cancer model. The value of combining these measurements lies not only in a more complete characterization of the cancerous tissue being imaged but in reduced scan time and more efficient use of resources.

**Necessary Technical and Analytical Developments**

Success with preclinical studies encouraged a more translational focus. In order to enable clinical trials, several specific technical developments were necessary. In the following section, we will outline some of the recent technical progress and note additional opportunities.

**A Device for Polarization**

Over the past 10 years, there have been significant improvements in polarizer hardware, from initial prototypes suitable for rodent exams to current commercial products that can support human studies. The performance in terms of polarization and speed of delivery has been adequate for initial [1-13C]pyruvate studies, but further developments are needed to achieve higher and faster polarizations reliably with increased cost-effectiveness, and to streamline methods of HP probe sterile delivery for pyruvate and other HP probes for future clinical research. Next-generation polarizers that are optimized for preclinical research will also be vital for supporting the development of new hyperpolarized agents and their use in basic science and translational research.

**Imaging Hardware**

Another important commercial goal should be improved 13C MR imaging hardware. While each major MR scanner vendor offers product hardware enabling the excitation and detection of hyperpolarized signals at the 13C frequency, several additional modifications would significantly improve the performance and applicability of this technology. Commercially available double-tuned body coils would greatly benefit human studies by allowing uniform excitation for 13C over any target disease site, as is the case for conventional 1H MRI. Current studies have been limited by both the 13C detector hardware and short acquisition times due to metabolism, signal relaxation, and excitation losses; thereby necessitating the use of strategies that more efficiently encode magnetization. As in 1H MRI, detector arrays with a high number of elements can facilitate higher acceleration rates to generate images faster and with increased spatial coverage and resolution. For optimal clinical studies, scanners with a greater number of receive channels (at least 32 channels) are needed to support 13C detector arrays with geometries that are optimized for all
body regions. Dual-tuned or nested receive arrays that would permit high-quality “standard of care” 1H MRI alongside sensitive 13C detection without repositioning or replacing coils in order to enhance patient comfort and workflow. Higher-performance gradients will also be critical for improving the speed, coverage, and performance of HP 13C MRI, which requires four times higher gradient strengths to achieve the same effect as for 1H MRI. The progress seen in highly parallel acquisition of 1H MRI over the past few years provides reason to believe that these radiofrequency (RF) coil challenges can be met within the constraints imposed by currently available gradient bores. The increased costs would be a very small fraction of total system cost and easily justified by the greatly enhanced capabilities. The development of appropriate phantoms that enable testing of new techniques for HP 13C MRI prior to human studies is also important for advancing the field. Static phantoms containing 13C-enriched compounds facilitate technical development and quality assurance testing to confirm scanner and coil performance at thermal equilibrium, while dynamic phantoms that simulate the kinetics of chemical conversion in vivo are important to develop and validate quantitative dynamic imaging measurements.

**Acquisition Methods for Human Studies**

The high signal-to-noise ratio provided by this hyperpolarization technique makes high-resolution acquisitions feasible. However, rapid metabolism and short T1 relaxation times can limit the matrix size—and thus the spatial resolution and coverage possible—with conventional phase-encoding. The MR acquisition techniques used for initial animal studies and the first human trial were limited in spatial coverage (typically <8 cm) and dynamic temporal information. This clinical trial used single-slice dynamic 13C echo-planar spectroscopic imaging (EPSI) in some patients to estimate the correct starting time for a 12-second 3D EPSI single time-point acquisition in subsequent patients with a small FOV of 8-10 cm. Dynamic 1D EPSI measurements efficiently encode frequency and space along the readout direction following a single excitation. Extension to multiple spatial dimensions requires additional excitations and phase encoding repetitions for each dynamic time point. New acquisition and analysis techniques are needed for volumetric, dynamic HP MR data with improved spatial coverage and temporal resolution. Most preclinical and clinical research studies have used spectroscopic-based acquisitions, but imaging-based acquisitions including balanced steady-state free precession sequences, spectral-selective echo-planar, and spiral trajectories have clear advantages in terms of speed and ease of implementation and analysis. Methods combining 13C and 1H excitation and reception could benefit the detection of many metabolites via decoupling and indirect detection.

**Reconstruction, Dynamic Modeling, and Enzyme Rate Constants**

Ideal dynamic MRSI data would be resolved in three spatial dimensions, the spectral dimension, and time with adequate coverage and speed to enable reliable quantification of metabolic parameters. Fortunately, the spectrum is sparse, with only a few spectral lines. In addition, the time dimension is slowly varying. These two features allow the amount of encoding required to be greatly reduced by using compressed sensing reconstructions along with low-rank or model-based reconstruction in the temporal dimension. Spatial data reduction strategies, including parallel and constrained imaging methods, are crucial for reducing the number of excitations that are necessary to reconstruct dynamically changing data. Fewer
excitation pulses preserve HP magnetization, allowing for increased coverage, higher excitation angles, or prolonged interaction with target biology. Optimized excitation schemes are required to permit further sensitivity enhancement.

Parallel imaging reconstructions can be challenging since signal at thermal equilibrium is too weak for practical measurement of sensitivity maps. Autocalibrating methods such as GRAPPA (GeneRalized Autocalibrating Partial Parallel Acquisition) can avoid wasting polarization and imaging time acquiring sensitivity maps but can be problematic because the fully sampled central region can be a large fraction of the sampled k-space volume which limits acceleration. Care must also be taken to ensure that undersampled parallel imaging data are acquired in such a way that the data are self-consistent enough to satisfy fundamental assumptions about the relationship between undersampled data. Alternatively, undersampled k-space data can be used to compute the coil sensitivities as with a calibration-less approach for HP $^{13}$C MR. Further investigations are needed to develop acquisition strategies that minimize uncertainty while maximizing the efficiency of spatial, temporal, and spectral encoding—including methods that exploit redundant information that could be derived from conventional $^1$H MRI.

MRI of hyperpolarized substrates is unique among diagnostic imaging modalities in its ability to provide information about dynamic chemical interactions and imaging agent metabolism. New approaches for characterizing the transient interaction between the imaging agent and targeted biological processes are therefore required. A variety of approaches have been proposed, including semi-quantitative area under the curve measurements—such as the normalized lactate ratio—that reflect the ratio of locally observed product to precursor and product, “snapshot” measurements of metabolite

---

**Figure 2.** Images are from a representative patient with a current PSA of 3.6 ng/ml, who had biopsy-proven prostate cancer in the left apex (Gleason grade 3 + 4) and received the highest dose of hyperpolarized [1-13C]pyruvate (0.43 ml/kg). (A) A focus of mild hypointensity can be seen on the T2-weighted image, which was consistent with the biopsy findings. (B to D) 2D localized dynamic hyperpolarized [1-13C]pyruvate and [1-13C]lactate from spectral data that were acquired every 5 seconds from voxels overlapping the contralateral region of prostate (turquoise), a region of prostate cancer (yellow), and a vessel outside the prostate (green). The dynamic data were fit to provide $k_{PL}$ as described previously. Figure taken from Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PEZ, Harzstark AL, Ferrone M, et al. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate. *Science Translational Medicine* 2013;5:198ra108-198ra108.
distribution, or ratiometric values at a single time point. Pharmaco-kinetic analysis of dynamic multispectral data has shown the ability in both preclinical and human studies (Figure 1) to derive rate constants for substrate conversions such as $k_{PL}$, the spectroscopic/imaging biomarker for the calculated rate at which HP pyruvate is converted into lactate. Quantitative measures such as $k_{PL}$ can provide important quantitative parameters for many applications where precise measurements are needed to quantify changes in specific drivers of aerobic glycolysis. Recent literature shows the strong correlation between perfusion and metabolic measures of $k_{PL}$ with cancer aggressiveness and response to therapy. To realize the inherent promise of the unprecedented new information afforded by HP substrates, further research is critically needed to develop and test new accurate, reproducible quantitative analysis methods.

**Translation to Patients with Cancer**

The first-in-human study convincingly demonstrated that injection of HP [1-13C]pyruvate is safe and that imaging metabolic products of hyperpolarized [1-13C]pyruvate metabolism is feasible. Since then, a number of significant technical improvements relevant to improving data quality and preserving safety have been implemented. These include improved technology and strategies for generating sterile hyperpolarized material using a commercial device, the SPINlab, new MR data acquisition sequences, and multichannel 1H/13C radio frequency RF coils. Pictured in Figure 2 is the workflow for the current-generation SPINlab which is now used routinely in patient studies and provides automated polarization, dissolution, and quality assurance system. The SPINlab polarizer uses a 5-T magnetic field and operates at ~0.8 K. It has the capacity to polarize up to four samples simultaneously, thus opening the door for the injection of multiple HP probes within a single imaging exam. A critical part of the SPINlab polarization and quality assurance process is the fluid path that enables polarization in a closed system to minimize the potential for microbial contamination. Compared to the initial human study using a prototype polarizer in a clean room, the achievable polarization of [1-13C]pyruvate has more than doubled (from ≈18% to ≈40%), and the time to delivery of HP 13C pyruvate was reduced (from ≈68 seconds to ≈55 seconds). Around the world, seven sites have performed human exams using the SPINlab polarizer, and more than 20 have been installed.

While initial patient studies have focused on [1-13C]pyruvate, [2-13C]pyruvate has recently been FDA approved and is being added...
Table 1. Current Hyperpolarized 13C MRI Clinical Trials—ClinicalTrials.gov

| Study Title                                                                 | Indication                                                                 | Institution                                                                 |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------------|
| Hyperpolarized 13C-Pyruvate MRI Study                                       | Cancer                                                                     | University College London, London, UK                                       |
| Effect of Cardiotoxic Anticancer Chemotherapy on the                        | Cardiovascular diseases                                                   | UT Southwestern–Advanced Imaging Research Center, Dallas, TX, USA           |
| Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria                      | Breast neoplasms                                                          | M D Anderson Cancer Center, Houston, TX, USA                                |
| Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Patients With Central Nervous System Tumors | Prostate adenocarcinoma                                                    | Stanford University School of Medicine Palo Alto, CA, USA                   |
| Stage IIIB prostate cancer AJCC v8 (and 7 more...)                          | Metastatic malignant neoplasm in the central nervous system                | UT Southwestern–Advanced Imaging Research Center, Dallas, TX, USA           |
| Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate | Traumatic brain injury                                                    | UT Southwestern–Advanced Imaging Research Center, Dallas, TX, USA           |
| Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway   | Fatty liver                                                                | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intraparenchymal Metastasis Treated With (SRS) | Brain metastases                                                          | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| Hyperpolarized 13C Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer | Uterine cervical neoplasms                                                 | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy | Breast cancer                                                              | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI) | Brain tumor adult                                                         | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| UTSW HP [13-C] Pyruvate Injection in HCM                                    | Cardiomyopathy, hypertrophic                                               | UT Southwestern Medical Center - Advanced Imaging Research Center, Dallas, TX, USA |
| Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors | Pediatric brain tumors                                                    | UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA |
| Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | Prostate cancer                                                           | University of California, San Francisco San Francisco, CA, USA              |
| Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer | Prostate cancer                                                           | University of California, San Francisco San Francisco, CA, USA              |
| Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer              | Prostate cancer                                                           | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection | Hypertension                                                              | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection | Hypertrophy                                                               | Sunnybrook Health Sciences Centre Toronto, Ontario, Canada                  |
| A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer | Prostate neoplasms                                                        | University of California, San Francisco San Francisco, CA, USA              |
| MRI With C13 Pilot Study Prostate Cancer                                    | Prostate cancer                                                           | University of California, San Francisco San Francisco, CA, USA              |
| Characterization of Hyperpolarized Pyruvate MRI Reproducibility             | Malignant solid tumors                                                    | Memorial Sloan Kettering Cancer Center New York, NY, USA                     |
| Hyperpolarized Pyruvate Injection In Subjects With Prostate Cancer          | Prostate cancer                                                           | University of California San Francisco                                      |

Early patient validation studies involving test–retest reproducibility, correlations with pathologic findings, and clinical outcomes such as survival and disease progression after treatment have been initiated (data available from clinicaltrials.gov). In a study utilizing 2D dynamic EPSI of preprostatectomy prostate cancer patients (NCT02421380), time to max pyruvate was reproducible when corrected for the arterial input function with no significant difference observed in repeat injections of the same patient within the same exam. In two recent clinical trials of prostate cancer patients preprostatectomy (NCT02526360) and before and after treatment (NCT02911467), a 3D dynamic compressed sensing EPSI sequence was used to obtain full prostate coverage and to model the apparent rate of pyruvate to lactate conversion, kPL. In the setting of advanced prostate cancer, early (6 weeks) after effective androgen deprivation therapy, there was a significant early reduction in kPL that receded changes in mp-1H MRI and predicted clinical response (Figure 3). Comparison with current state-of-the-art imaging modalities such as 1H MRI is key to determining the added value of HP 13C MRI, and with current HP 13C MRI studies expanding to metastatic sites within the body, the synergy of HP MRI with currently used PET probes will also need to be investigated.

There are currently a number of single-institution HP 13C MRI clinical trials in the setting of breast, cervical, liver, and brain cancer, and an initial multisite clinical trial for prostate cancer (Table 1). Following promising preclinical studies in brain tumors, multiple sclerosis, and traumatic brain injury, the feasibility of using HP 13C MRI for evaluating brain metabolism in patient studies was recently demonstrated. These studies demonstrated that 13C pyruvate are transported across the blood brain barrier and that conversion to [1-13C]lactate can be detected in regions of both tumor and normal brain. Interestingly, the rate of conversion in normal brain was substantially higher than had previously been observed in anesthetized preclinical models. For dynamic slab-localized and 2-D...
echo planar spectroscopic imaging data with 4-8 ml spatial resolution, it was also possible to observe the conversion of HP pyruvate to bicarbonate, which may discriminate between tumor and normal brain. Additional studies are needed to optimize the pulse sequences, RF coils, and experimental design to observe all three resonances at a finer resolution and with volumetric coverage. Single-institution studies that have been funded by the NIH include protocols for obtaining data from the normal brain, in primary brain tumors prior to image-guided surgery, and for comparing that conversion to $[^{1-13}C]$lactate/$[^{1-13}C]$pyruvate in patients pre- and posttreatment with radiation and temozolomide.

There are also several clinical trials investigating noncancerous diseases, such as cardiomyopathy, hypertrophy and hypertension, and fatty liver disease (Table 1). Altered cardiac energetics is known to play an important role in the progression toward heart failure, and a recent study demonstrated the feasibility of assessing pyruvate metabolism in vivo in humans.97 The appearance of $[^{13}C]$bicarbonate signal after administration of hyperpolarized $[^{1-13}C]$pyruvate was readily detected in a cohort of healthy controls, suggesting that this technology may 1 day allow a direct measure of flux through the PDC in the in vivo human myocardium, providing a means for understanding therapeutic approaches that target metabolism.

While prior and ongoing HP $^{13}$C MRI patient studies have addressed many of the initial obstacles, there remain a number of challenges to the robust clinical translation of hyperpolarized $[^{1-13}C]$pyruvate MRI and its full FDA approval, as well as the translation of other new hyperpolarized probes into the clinic. These challenges are discussed in the following section.

### Challenges in Translation to Clinical Research and Practice

Compared to current metabolic imaging methods based on positron tomography, HP $^{13}$C MRI technology offers superior information yield about fluxes in metabolic pathways without the constraints of ionizing radiation. Nevertheless, while other potential benefits such as safety and patient acceptability may be substantial, the central question for clinical translation is whether HP $^{13}$C MRI provides actionable clinical information that is inaccessible by other methods. In examining how this question can be answered in the affirmative, we can take some cues from the use of FDG PET/CT.

#### The Clinical Role of Imaging in Cancer

The traditional clinical roles for imaging in cancer are detection, diagnosis, staging, and monitoring therapy.114 More specifically, imaging techniques are typically used in the clinic to detect the tumor through screening; to guide cancer diagnosis, including tissue sampling; and to determine the extent of cancer spread. More recently, molecular imaging in particular has been used as a cancer biomarker to help direct treatment.115,116 Already demonstrated in animal models110 and initial patient studies,107 this capacity to rapidly detect response to treatment is perhaps the most promising in terms of clinical translation. Because a response to therapy prior to any change in tumor volume could occur within days, or even hours, the ability to detect this change could redirect therapy to improve therapeutic efficacy and avoid unnecessary toxicity for ineffective treatments, potentially saving lives and alleviating suffering.

The complexity, expense, and requirement for administering an imaging agent will likely limit HP MRI’s role as a primary screening tool. However, coupled to blood or urine metabolic biomarkers indicative of cancer risk and specific cancer metabolic signatures,117 HP MRI could provide a very powerful, targeted detection tool in stratified populations. It could play a key role in diagnosis, for example, as metabolic features identified by HP MRI might provide a both sensitive and specific means of identifying cancer and clarifying the benign or malignant nature of findings seen on anatomic imaging—as is the case in the application of FDG PET to pulmonary nodules detected by CT.118 Since HP MRI is readily coupled to the anatomic information acquired from standard MRI, it may also be particularly helpful in directing tissue sampling by identifying the sites most suspicious for cancer or, in the case of large cancer or widespread lesions, indicating the lesions that appear most aggressive. Finally, HP MRI could play a role in stratifying tumors identified by other imaging modalities. Also, the application of HP MRI for systemic staging is unlikely in the short term as it would require a whole-body capability similar to that of PET/CT, the development of which would have to overcome several technical challenges. However, as discussed above, these technical challenges are beginning to be addressed in ongoing phase II clinical trials of metastatic cancer.

Our understanding of cancer metabolism is primarily based on cell and murine models whose relevance to human malignancies is unclear. Consequently, in addition to the traditional roles of imaging in cancer management, HP MRI could provide clinical value based on its capacity to identify specific therapeutic targets in vivo in humans, i.e., serve as companion diagnostics. Accordingly, the presence of accelerated lactate production could direct the use of LDH inhibitors, while altered mitochondrial metabolism might suggest therapeutic options to renormalize metabolic activity.

### How Could HP Information Change a Therapeutic Decision?

Since the publication of the first white paper,3 a number of reports have appeared on the evaluation of cancer biomarkers and cancer imaging methods.114,117,119–122 HP $^{13}$C MRI holds great promise as an imaging biomarker of cancer. An imaging biomarker has been defined as an anatomic, biochemical, or molecular parameter detectable with an imaging method that is useful for establishing the presence or severity of disease.123,124 As we have already mentioned, metabolic alteration is an important phenotypic feature of cancer that predicts disease behavior and can itself be a therapeutic target.121,125 A critical consideration in the translation of a new biomarker into the clinic is the impact of the test necessary for obtaining this biomarker on clinical practice and patient outcome.119 In other words, does the test lead to better, more effective, and/or more cost-effective patient treatment? As a cancer molecular imaging biomarker, HP $^{13}$C MRI has the potential to address the following five clinical needs.115

First, HP MRI could prove beneficial by detecting disease prior to its initial clinical manifestation—in high-risk patients, for example—or as a secondary diagnostic test, indicating the likelihood that abnormal findings from screening or staging studies represent a malignancy. It could also prove valuable by helping to stratify disease severity after a diagnosis. Second, HP MRI could identify specific sites for tissue biopsy for cancer diagnosis and characterization. A third important benefit would be the capacity to predict disease progression based on evidence of metabolic hyperactivity or the integrity of metabolic pathways that enable metastasis. Fourth, HP MRI may provide an early, pharmacodynamic measure of drug efficacy, which could in turn predict the likelihood of therapeutic futility, by measuring the impact of a given drug on regional cancer.
metabolism. If validated, this would be a significant clinical contribution, as it would enable the avoidance of ineffective chemotherapy with the attendant morbidity and expense. Finally, HP MRI could prove useful in evaluating prognosis and indicating overall response—using the eradication of aberrant metabolism as a highly predictive indicator of disease resolution, akin to the use of FDG PET/CT in lymphoma. In this context, the role of HP would be to determine whether or not treatment has eliminated the cancer, as well as to help determine if there is a need for additional treatment by predicting the likelihood of disease relapse or progression. In summary, biomarker applications are likely to represent the most compelling use of HP 13C MRI in relation to cancer since its unique ability to characterize and quantify cancer metabolism provides a means for inferring the impact of targeted therapeutic interventions.

What Will a Clinician Look for in Studies of HP Validation?

Experience with cancer diagnostics suggests that the general term “validation” may refer to distinct criteria: validity with respect to analytical results, validity for the purpose of a clinical diagnosis, and validity for the purpose of modifying patient care, which could also be termed clinical utility. In order to support the use of HP 13C MRI in clinical trials and clinical practice, investigations relevant to all three classes of data will be needed.

Analytic validity will be an important question, as clinicians will need to understand what HP 13C MRI is measuring and see evidence that these measurements are accurate. One approach to establishing the analytic validity of HP MRI is to compare its results with those of other PET-based tracer experiments. Demonstrating the reproducibility of hyperpolarized imaging exams is another important step and will require establishing standardized and repeatable methods for HP MR image acquisition and interpretation. Clinical validity, on the other hand, refers to the capacity of a test to separate a given patient population into two groups, such as those with and without a disease. To establish their clinical validity, HP MRI results must be compared to an accepted clinical standard such as the tissue or laboratory-based assays with which oncologists are most comfortable. Another important aspect of demonstrating HP MRI’s clinical validity will be its comparison to FDG and other PET imaging methods, and for this reason, investment in facilities capable of performing both exams is critical.

It is important to acknowledge, however, that establishing the clinical validity of a given technology does not in and of itself demonstrate that this technology should be used in patient care decisions. Rather, that determination is ultimately based on clinical utility, which refers to the technology’s capacity to appropriately direct patient care. In assessing the clinical utility of HP 13C MRI, clinicians will look for validation against clinical outcomes, accuracy (sensitivity, specificity, receiver operating characteristic area) versus a reference standard in diagnostic applications, and predictive accuracy in assessing therapeutic response. It will therefore be important to know to what extent the data provided by HP MRI accurately reclassify a patient, after all conventional studies are complete, into the proper category—classified either as normal (with a normal HP exam) or as disease (with an abnormal HP exam). Additional criteria will include the risk or discomfort of the exam relative to the new information it provides and, of course, the cost. Utility will be a key component of later clinical trials, in which assessment of the impact on patient outcomes and the cost of medical care provide data for coverage decisions by payers, which is one of the most important determinants of whether or not a new test is actually used in the clinic.

Comparison to Positron Tomography

Lessons learned from other quantitative molecular methods such as PET can help guide the approach to quantitative image analysis using HP MRI. For example, studies have shown that more sophisticated quantitative methods such as compartmental kinetic analysis can improve the ability to measure therapeutic response and predict patient outcomes; however, this improvement must be balanced against the ability to implement more complex methods in the clinic. Experience suggests that necessary simplification is best achieved by collecting detailed data in early studies and then testing the impact of simplification against more rigorous analytic approaches.

Combining HP MRI and PET data in kinetic analysis may be especially powerful in characterizing cancer metabolism, as the two methods provide complementary information. Long half-life and relatively straightforward image quantification make PET a robust method for quantifying flux through certain specific biochemical pathways, such as the flux of glucose through hexokinases as a measure of glycolysis or of thymidine through TK as a measure of cellular proliferation. However, since isotopic emissions are not impacted by the chemical species to which the isotope is attached, PET provides no information about the nature of the molecule attached to the label. HP 13C MRI, on the other hand, provides exquisite information on the evaluation of metabolites of the injected substance—such as for lactate from pyruvate—while its shorter half-life makes studies of metabolic trapping difficult. Taken together, the two methods can provide comprehensive information on metabolic fluxes, especially at major branch points in metabolic pathways such as the conversion of pyruvate to lactate in glycolysis.

Future Directions: Initial Studies and Clinical Study Design

Early Clinical Trials. Existing guidelines for designing and reporting on clinical trials of biomarkers provide a helpful template for HP 13C MRI. Early studies must refine and test robust methods for image acquisition and analysis to provide a uniform (and uniformly accepted) approach to be used in subsequent clinical trials. Early studies should also include tests of repeatability/precision to measure the qualitative and quantitative variability of HP imaging results, typically using a test/retest paradigm. Guidelines based on results from early clinical trials are important for subsequent trials and eventual clinical use, as the NCI consensus guidelines on FDG PET/CT have demonstrated. Finally, early clinical trials should validate HP 13C MRI against an accepted reference standard for cancer diagnosis and characterization, typically based on tissue sampling. This reference standard can be the presence or absence of cancer for diagnostic applications, or specific assays that might serve as a reference for imaging measures and which are often established in preclinical studies. In addition to standardizing imaging approaches, reporting of adverse events also could be standardized to facilitate regulatory approval down the road.

The latter phase of imaging trials for biomarker applications should evaluate new imaging tests for their accuracy in predicting important clinical cancer outcomes such as therapeutic response, progression-free survival, and overall survival. Early studies must establish the
value in clinical trials of HP $^{13}$C MRI as integrated markers, where novel imaging is embedded in a clinical trial but is collected in a purely observational fashion for comparison against clinical outcomes measured in the treatment trial. This has been validated in integral biomarker trials, the imaging marker can be used to direct therapy in a clinical trial and, later, in clinical practice. An example can again be found in the application of FDG PET/CT to lymphoma, where the resolution of abnormal FDG uptake, known as a complete metabolic response, was shown to be highly predictive of disease-free survival and is now used as an integral marker in clinical trials and for clinical practice.

**Multisite Trials.** Multisite clinical trials will be expected prior to FDA approval of [1-13C]pyruvate as an imaging agent, and certain specific obstacles will have to be addressed in designing them. In addition to requiring novel imaging hardware, acquisition methods, and analysis, HP $^{13}$C MRI carries the added challenge of requiring the administration of a short-lived, locally produced imaging probe, the production of which requires onsite personnel with expertise in producing HP agents, monitoring their quality, and assuring patient safety and regulatory compliance. The ability to produce uniformly high-quality HP imaging agents across multiple centers is therefore a crucial step in moving to multicenter clinical trials and eventual clinical practice. Once again, some lessons can be learned from recent multisite tests of investigational PET probes, which share many of these requirements.

The foremost requirement is that of validated, uniform standards for probe production that will support equivalent probe quality across all sites involved participating in multicenter trials. This allows operation under a common regulatory framework—for example, an NCI-held IND for multicenter clinical trials—and assures patient safety and consistency of the drug product. Standardized, robust image acquisition methods are also needed, as are methods for testing and qualifying equipment and personnel involved in HP MRI studies to ensure high-quality imaging data at all participating sites.

Experience suggests a multistep approach leading to multicenter trials for novel imaging approaches such as MRI of HP [1-13C] pyruvate will be key for obtaining full FDA approval. Early studies to test the potential accuracy and utility of new imaging methods are often best done in single-center studies at expert institutions invested in the technology. Early multicenter phase II trials should be small enough to assure the ability of sites to acquire the imaging data in a uniform and reproducible fashion and should validate the findings from single-center trials; indications supported by small multicenter trials can then be carried into larger phase III studies using well-defined, prospective procedures for image analysis, with study design and sample size calculations guided by results from smaller multisite or single-site trials. Larger phase II trials should include endpoints for safety and efficacy—in this case defined as diagnostic accuracy. These large studies should also gather information on therapeutic impact and cost-effectiveness, key data for coverage decisions by the Centers for Medicare and Medicaid Services and other payers.

**Education, Training, and Certification**

In addition to regulatory approval, translation to clinical practice will require training for staff members who produce HP probes and carry out HP $^{13}$C MR imaging. Imaging physicians will also need to be trained in this new imaging modality: not only how to interpret the data it provides but also how to safely and effectively administer HP imaging probes. Experience with other highly specialized imaging methods such as PET and breast MRI suggests that requirements for physician training and certification will be important in assuring uniform diagnostic quality across all sites of practice. Finally, even after clinical practice implementation, ongoing clinical research will be critical for sustaining and optimizing clinical use.

**Recommendations for Future Research**

Since the publication of the first NIH white paper on hyperpolarized $^{13}$C MRI in 2011, numerous preclinical studies have demonstrated this technology’s unique metabolic imaging capabilities in the context of cancer. There have now been over 200 HP $^{13}$C MRI human studies performed to date worldwide at 7 different medical centers, and over 5 more sites plan to initiate patient studies within the next 6 months. All of these studies have shown that HP $^{13}$C pyruvate MRI is safe and also effective in detecting key metabolic conversions in patients with a variety of diseases and even in normal volunteers. It is important to recognize that demonstrating the clinical safety and feasibility of HP MRI technology is not enough to ensure its widespread clinical implementation. If the latter is to be achieved, it will be because future trials are able to successfully establish its clinical utility. In addition, widespread clinical implementation also implies regulatory approval and reimbursement approvals around the world. Commercialization of HP [1-13C]pyruvate MRI will require a comprehensive regulatory and sponsorship strategy that will also depend on the potential clinical utility. We have developed a number of recommendations with this ultimate goal in mind.

First, it is necessary to continue refining the protocols, new HP agents, and investigative targets of ongoing preclinical studies in a translational direction with refined pharmacy methods for reliable, lower-cost production of sterile HP solutions. Also, it is valuable to verify that metabolic measurements in animal models of cancer and other disease states correspond to those performed in human disease, and to incorporate these measurements into disease hypothesis testing and development of new hyperpolarized agents. Improved quantitative analysis of metabolic signals and enzymatic rate kinetics obtained from HP [1-13C]pyruvate will be a critical aspect of this. It is also imperative to identify the metabolic network(s) associated with the metabolism of specific hyperpolarized agents in order to select the appropriate agent for the study of specific disease conditions and therapies, and to appropriately guard against incorrectly associating apparent metabolic changes with the wrong cause. Additionally, there is a need for more studies which focus on determining the origins of variability in therapeutic response through separate HP measures of uptake and metabolism, and to use these HP probes to identify and better understand therapeutic response and nonresponders at earlier time points.

Further efforts to develop improved imaging pulse sequences and RF coils for imaging different organs, agents, and disease states will be critical for increased quality, information content, and applicability. New RF hardware should enable body-coil transmit and multichannel (32 at least) reception for all parts of the body with both $^{13}$C and $^1$H frequency excitation and reception. Analysis methods for the reliable calculation of enzymatic rate constants, such as $k_{PL}$ for the LDH catalyzed conversion of pyruvate to lactate and $k_{PY}$ for pyruvate to bicarbonate, need to be refined and tested in patient and volunteer studies at multiple sites. In the context of cancer more specifically, another vital avenue for future studies will be the development of new HP agents capable of probing the ancillary and often-unexpected metabolic changes leading to increased cancer cell survival after...
therapy. Specialized MR pulse sequences for the new agents will be required and $^1$H detected $^{13}$C spectroscopy techniques should be developed and investigated for increased sensitivity with the added advantage that spatial information can be encoded at the $^1$H frequency.

There are also a number of needs to be addressed at an institutional level. First and foremost, the mechanism(s) for multisite clinical trials must be established—both through the identification of sites that possess the necessary equipment and by developing the appropriate investigative protocols. In order to support these efforts, it is important to promote the development of pedagogical resources for real-time metabolic imaging, perhaps through the establishment of new pre- and postdoctoral training programs focused on developing relevant techniques.

Finally, widespread clinical translation will not be possible without the continued development of robust collaborations among basic science investigators, clinical oncologists, and those with expertise in clinical study design. This collaborative work must be bolstered by strong partnerships between academia, funding agencies, and industry.

Acknowledgements

This report was initiated through discussions with representatives of the NCI Cancer Imaging Program and other NIH extramural programs (National Institute of Diabetes and Digestive and Kidney Diseases; National Heart, Lung, and Blood Institute; National Institute of Biomedical Imaging and Bioengineering; and NIH Research Infrastructure Programs). The initial draft was reviewed and edited by over 60 scientists, followed by extensive discussions at a workshop at the ISMRM meeting in May 2017 with more than 52 scientists from academia, industry, and federal agencies from the United States and other countries. The authors appreciate the assistance from NIH extramural program staff Drs. Huiming Zhang, Maren Laughlin, Guoying Liu, Larry Clarke, Paula Jacobs, Janet Eary, and Lalitha Shankar during the development of this report and for organizing the workshop. The authors would also like to thank other contributors, namely, Drs. Michael Boss and Karl Stupic from NIST, Dr. Murali C Krishna from NCI intramural, and Dr. Matthew G. Vander Heiden from MIT.

References

[1] Cairns RA, Harris IS, and Mak TW (2011). Regulation of cancer cell metabolism. Nat Rev Cancer 11, 85–95. https://doi.org/10.1038/nrc2981.

[2] Timm KN, Kennedy BWC, and Brindle KM (2016). Imaging tumor metabolism to assess disease progression and treatment response. Clin Cancer Res 22, 5196–5203. https://doi.org/10.1158/0821-6411.CCR-16-0159.

[3] J. Kurhanewicz, D. B. Vigneron, K. Brindle, E. Y. Chekmenev, H. Happer, and E. Y. Chekmenev, A. Comment, C. H. Cunningham, R. J. Deberardinis, G. G. Green, M. O. Leach, S. S. Rajan, et al.

[4] Teo S-S and Keshari KR (2015). Novel approaches to imaging tumor metabolism. Nat Rev Cancer 15, 165–173. https://doi.org/10.1038/nrc3991.0003781111.

[5] Siddiqui S, Kadlecik S, Pourfathi M, Xin Y, Mamhzer H, Hamedani H, Drachman J, Ruppert K, Clapp J, and Rizi R (2017). The use of hyperpolarized carbon-13 magnetic resonance for molecular imaging. Adv Drug Deliv Rev 113, 3.

[6] Zhang H (2014). The potential of hyperpolarized $^{13}$C MRI in assessing signaling pathways in cancer. Acad Radiol 21, 215–222. https://doi.org/10.1016/j.acra.2013.11.015.

[7] Bowers CR and Weitekamp DP (1987). Parahydrogen and synthesis allow dramatically enhanced nuclear alignment. J Am Chem Soc 109, 5541–5542. https://doi.org/10.1021/ja00252a049.

[8] P. Bhattacharya, E. Y. Chekmenev, W. F. Reynolds, S. Wagner, N. Zacharias, H. R. Chan, R. Burger, B. D. Ross, Parahydrogen-induced polarization (PHIP) hyperpolarized MR receptor imaging in vivo: a pilot study of $^{13}$C imaging of atheroma in mice. NMR Biomed 24, 1023.

[9] Walker TG and Happer W (1997). Spin-exchange optical pumping of noble-gas nuclei. Rev Mod Phys 69, 629–642. https://doi.org/10.1103/RevModPhys.69.629.

[10] Mugler JP, Alves TA, Buser IC, Dregely IM, Mata JF, and Miller GW, et al. (2010). Simultaneous magnetic resonance imaging of ventilation distribution and gas uptake in the human lung using hyperpolarized xenon-129. PNAS 107, 21707–21712. https://doi.org/10.1073/pnas.1011912107.

[11] Gabelli C, Reynolds S, Lavie A, Payne GS, Leach MO, and Elykyn TR (2008). Therapeutic target metabolism observed using hyperpolarized $^{15}$N choline. J Am Chem Soc 130, 4598–4599. https://doi.org/10.1021/ja8001293.

[12] Fru S, Babalakrishnan A, Bok RA, Anderson B, Larson PEZ, and Nelson SJ, et al. (2012). $^{13}$C-pyruvate imaging reveals alterations in glycolysis that precede $^{13}$C Myc-induced tumor formation and regression. Cell Metab 14, 131–142. https://doi.org/10.1016/j.cmet.2011.04.012.

[13] Keshari KR, Sriram R, Van Crikkenig M, Wilson DM, Wang ZJ, and Vigneron DB, et al. (2017). Metabolic reprogramming and validation of hyperpolarized $^{13}$C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor. Prostate 73, 1171–1181. https://doi.org/10.1002/pros.22665.

[14] Sriram R, Van Crikkenig M, De Los Santos J, Keshari KR, Wilson DM, Pehel D, Kurhanewicz J, and Wang ZJ (2016). Non-invasive differentiation of benign renal tumors from clear cell renal cell carcinomas using clinically translatable hyperpolarized $^{13}$C pyruvate magnetic resonance. Tomography 2, 35.

[15] Sriram R, Van Crikkenig M, Hansen A, Wang ZJ, Vigneron DB, Wilson DM, Keshari KR, and Kurhanewicz J (2015). Real-time measurement of hyperpolarized lactate production and efflux as a biomarker of tumor aggressiveness in an MR compatible 3D cell culture bioreactor. NMR Biomed 28, 1141.

[16] Rajeshkumar NV, Dutta P, Yabusuchi S, de Wilde RF, Martinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, and Hidalgo M, et al. (2013). Targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res 75, 3355.

[17] Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, and Ronen SM (2016). Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget 7, 3494.

[18] Day SE, Kettunen MI, Gallagher FA, Hu DE, Leriche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, and Brindle KM (2007). Detecting tumor response to treatment using hyperpolarized $^{13}$C magnetic resonance imaging and spectroscopy. Nat Med 13, 1582.

[19] Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil P, Costello JF, Pieper RO, and Ronen SM (2016). IDH1 Mutation induces reprogramming of pyruvate metabolism. Cancer Res 75, 2999.

[20] Park JM, Spielman DM, Jonsan S, Jang T, Merchant M, Hudson RE, Mayer D, and Recht LD (2016). Hyperpolarized $^{13}$C-lactate to $^{13}$C-bicarbonate ratio as a biomarker for monitoring the acute response of anti-vascular endothelial growth factor (anti-VEGF) treatment. NMR Biomed 29, 650.

[21] Saito K, Matsumoto S, Takakusagi Y, Matsuo M, Morris HD, Lizak MJ, Mutasinghe JP, Devashayam N, Subramanian S, and Mitchell JB, et al. (2015). $^{13}$C-MR Spectroscopic imaging with hyperpolarized $[1-^{13}]$Cpyruvate detects early response to radiotherapy in SCC tumors and HT-29 tumors. Clin Cancer Res 21, 5073.

[22] Wojtkowiak JW, Cornell HC, Matsumoto S, Saito K, Takakusagi Y, Dutta P, Kim M, Zhang X, Lees R, and Bailey KM, et al. (2015). Pyruvate sensitizes pancreatic tumors to hyposia-activated prodrug TH-302. Cancer Metab 3, 21.

[23] Prather J, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaemler K, Ronen SM, Nelson SJ, and Pieper RO (2014). Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res 74, 7115.

[24] Sandulache VC, Chen Y, Lee J, Rubinstein AS, Ramirez SD, Skinner HD, Walker CM, Williams MD, Tailor R, and Court LE, et al. (2014). Evaluation of hyperpolarized $[1-^{13}]$C-derivatives by magnetic resonance to detect ionizing radiation effects in real time. PLoS One 9, e87031.
Neoplasia

Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, Dutta P, Le A, Vander Jagt DL, Tsukamoto T, Martinez GV, Dang CV, and Bohndiek SE, Kettunen MI, Hu DE, and Brindle KM (2012). Hyperpolarized 13C pyruvate magnetic resonance spectroscopy of tumors. Cancer Res 73, 4190.

Chen AP, Chu W, Gu Y-P, Cunningham CH, and Cunningham CH (2013). Probing early tumor response to radiation therapy using hyperpolarized [1-13C] pyruvate in MDA-MB-231 xenografts. PLoS One 8:e56551. https://doi.org/10.1371/journal.pone.0056551.

Park JM, Recht LD, Jostan S, Merchant M, Jang T, Yen YF, Hurd RE, Spielman DM, and Mayer D (2013). Metabolic response of glioma to dichloroacetate inhibition in a hyperpolarized 13C magnetic resonance spectroscopic imaging. Neuro-Oncology 15, 433.

Lodi A, Woods SM, and Ronen SM (2013). Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells. NMR Biomed 26, 299–306. https://doi.org/10.1002/nbm.2848.

Radoul M, Chauham MM, Eriksson P, Wang AS, Phillips JJ, and Ronen SM (2016). MR Studies of glioblastoma models treated with Dual 13PK/mTOR inhibitor and temozolomide: metabolic changes are associated with enhanced survival. Mol Cancer Ther 15, 1113–1122. https://doi.org/10.1158/1535-7163.MCT-15-0769.

Bohdiek SE, Kettunen MI, Hu DE, and Brindle KM (2012). Hyperpolarized 13C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res 72, 854–864. https://doi.org/10.1158/0008-5472.CAN-11-2795.

Chauham MM, Ozawa T, Park I, Scott K, James CD, Nelson SJ, and Ronen SM (2012). Hyperpolarized 13C MR spectroscopic imaging can be used to monitor everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. Neuroumage 59, 193.

Dwed S, Durst M, Gringeri CV, Kosan Y, Gross C, Janich MA, Haase A, Glace S, Schweig S, and Schulze RF, et al (2016). Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized (13)C MRSI. NMR Biomed 29, 952.

Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, Park JM, Recht LD, Josan S, Merchant M, Jang T, Yen YF, Hurd RE, Spielman DM, and Mayer D (2013). Metabolic response of glioma to dichloroacetate inhibitor and temozolomide: metabolic changes are associated with enhanced survival. Mol Cancer Ther 15, 1113–1122. https://doi.org/10.1158/1535-7163.MCT-15-0769.

Keshari KR and Wilson DM (2014). Chemistry and biochemistry of 13C hyperpolarized magnetic resonance imaging. Chem Soc Rev 43, 1627–1659. https://doi.org/10.1039/c3cs36124b.

Bastiaansen JAM, Cheng T, Mishkovsky V, Duarte JM, COMMENT A, and Gruetter R (1830). In vivo enzymatic activity of acetylCoA synthetase in skeletal muscle revealed by (13)C turnover from hyperpolarized [1-13C]acetate to [1-13C]acetylcoenzyme A. Biochim Biophys Acta 2013, 4171–4178. https://doi.org/10.1016/j.bbabio.2013.03.023.

Flori A, Liserani M, Frijia F, Giovannetti G, Lionetti V, Casieri V, Positano V, Ball DR, Rowlands B, Dodd MS, Le Page L, Ball V, Carr CA, Clarke K, and Tyler DJ (2014). Hyperpolarized butyrate: a metabolic probe of short chain fatty acid metabolism in the heart. Mag Reson Imaging 27, 1601.

Kohler SJ, Tropp J, Hurd RE, and Yen YF, et al (2008). Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading. Cancer Res 68, 8607. https://doi.org/10.1158/0008-5472.CAN-07-4619.

Furuta T, Degani H, and Friedman I (2013). Hyperpolarized 13C MR studies of carbohydrate metabolism in living breast cancer cell cultures. NMR Biomed 26, 1831–1843. https://doi.org/10.1002/nbm.3024.

Keshari KR, Kurhanewicz J, Bok R, Larson PEZ, Vigneron DB, and Wilson DM (2011). Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc Natl Acad Sci U S A 108, 18606–18611. https://doi.org/10.1073/pnas.1106920108.

Bohdiek SE, Kettunen MI, Hu DE, Kennedy BW, Boren J, Gallagher FA, and Brindle KM (2011). Hyperpolarized [1-13C]-ascorbic and dehydroascorbic acid as metabolic probes of short chain fatty acid metabolism in the heart. Mag Reson Imaging 29, 1035.
acid: vitamin C as a probe for imaging redox status in vivo. *J Am Chem Soc* 133:11795.

[61] Timm KN, Hu DE, Williams M, Wright AJ, Kettunen MI, Kennedy BW, Larkin TJ, Dzien P, Marco-Rius I, and Bohndiek SE, et al (2017). Assessing oxidative stress in tumors by measuring the rate of hyperpolarized [1-13C] dehydroascorbic acid reduction using 13C magnetic resonance spectroscopy. *J Biol Chem* 292, 1737.

[62] Chaumeil MM, Larson PE, Woods SM, Cai L, Eriksson P, Robinson AE, Lupo JM, Vigneron DB, Nelson SJ, and Pieper RO, et al (2014). Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma. *Cancer Res* 74, 4247.

[63] Chaumeil MM, Larson PE, Yoshihara HA, Danforth OM, Vigneron DB, Nelson SJ, Pieper RO, Phillips JJ, and Ronen SM (2013). Non-invasive in vivo assessment of IDH1 mutational status in glioma. *Nat Commun* 4, 2429.

[64] Salamanca-Cardona L, Shah H, Poot AJ, Correa FM, Di Gialleonardo V, Lui H, Miloshev VZ, Granlund KL, Tee SS, and Cross JR, et al (2017). In vivo imaging of glutation metabolism to the oncometabolite 2-hydroxyglutarate in tumors. *Cancer Res* 77, 3207.

[65] Moreno KX, Satapati S, DeBerardinis RJ, Burgess SC, Malloy CR, and Merritt ME (2014). Real-time detection of hepatic gluconeogenic and glycogenolytic states using hyperpolarized [2-13C]dihydroxyacetone. *J Biol Chem* 289, 35859–35867. [https://doi.org/10.1074/jbc.M114.613265](https://doi.org/10.1074/jbc.M114.613265).

[66] Chen W, Khemtong C, Jiang W, Malloy CR, and Sherry AD (2016). Metabolism of Hyperpolarized 13C-Acetoacetate/8-Hydroxybutyrate Reveals Mitochondrial Redox Status in Perfused Rat Hearts. Presented at the ISMRM 24th Annual Meeting, Singapore; 2016.

[67] von Morze C, Bok RA, Reed GD, Ardenkjær-Larsen JH, Kurhanewicz J, and Vigneron DB (2014). Simultaneous multiagent hyperpolarized [13C] perfusion imaging. *Magn Reson Med* 72, 1599–1609. [https://doi.org/10.1002/mrm.25071](https://doi.org/10.1002/mrm.25071).

[68] Lau AZ, Miller JJ, Robson MD, and Tyler DJ (2016). Simultaneous assessment of cardiac metabolism and perfusion using copolarized [1-13C] pyruvate and [13C] urea. *Magn Reson Med* :https://doi.org/10.1002/mrm.26106. [https://doi.org/10.1002/mrm.26106](https://doi.org/10.1002/mrm.26106).

[69] Banko JA, Walker CM, Ramirez MS, Stefan W, Fuentes D, Merritt ME, Lee J, Sandulache VC, Chen Y, and Phan L, et al (2015). Kinetic modeling and constrained reconstruction of hyperpolarized [1-13C]pyruvate offers improved metabolic imaging of tumors. *Cancer Res* 75, 4708.

[70] Bohndiek SE, Kettunen MI, Hu DE, Witney TH, Kennedy BW, Gallagher FA, and Brindle KM (2010). Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy. *Mol Cancer Ther* 9, 3278.

[71] Salamanca-Cardona L and Keshar KR (2015). 13C-labeled biochemical probes for the study of cancer metabolism with dynamic nuclear polarization-enhanced magnetic resonance imaging. *Cancer Metab* https://doi.org/10.1186/s40170-015-0136-2.

[72] Najac C, Chaumeil MM, Kohanbash G, Guglielmetti C, Gordon JW, Okada H, and Ronen SM (2016). Detection of inflammatory cell function using [13C] magnetic resonance spectroscopy of hyperpolarized [6-13C]arginine. *Sci Rep* 6, 31397.

[73] Chen HY, Larson PEZ, Bok RA, von Morze C, Sriman R, Delos Santos R, Delos Santos J, Gordon JW, Bahrami N, and Ferrone M, et al (2017). Assessing prostate cancer aggressiveness with hyperpolarized dual-agent 3D dynamic magnetic imaging of metabolism and perfusion. *Cancer Res* 77, 3207.

[74] Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjær-Larsen JH, Zandt R, Jensen PR, Karlsson M, Golman K, and Lerche MH, et al (2008). Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. *Nature* 453, 940.

[75] Gallagher FA, Kettunen MI, and Brindle KM (2011). Imaging pH with hyperpolarized 13C. *NMR Biomed* 24, 1006–1015. [https://doi.org/10.1002/nbm.1742](https://doi.org/10.1002/nbm.1742).

[76] Schroeder MA, Swietach P, Atherton HJ, Gallagher FA, Lee P, Raddi GK, Clarke K, and Tyler DJ (2016). Measuring intracellular pH in the heart using hyperpolarized carbon dioxide and bicarbonate: a 13C and 31P magnetic resonance spectroscopy study. *Cardiovasc Res* 106, 82.

[77] Scholz DJ, Janich MA, Kollisch U, Schulte RF, Ardenkjær-Larsen JH, Frank A, Haase A, Schweiger M, and Menzel MI (2015). Quantified pH imaging with hyperpolarized (13)C bicarbonate. *Magn Reson Med* 73, 2274.

[78] Drachman N, Kadlecsek S, Pourfathi M, Xin Y, Proffka H, and Rizi R (2016). In vivo pH mapping of injured lungs using hyperpolarized [1-(13)C]pyruvate. *Magn Reson Med* :https://doi.org/10.1002/mrm.26473.
Zhu Z, Zhu X, Ohliger M, Cao P, Tang S, Gordon JW, Carvajal L, Shin PJ, Harrison C, Yang C, Jindal A, DeBerardinis RJ, Hooshyar MA, Merritt M, Weber WA, Gatsonis CA, Mozley PD, Hanna LG, Shields AF, Aberle DR, Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O'Shaughnessy J, Guyton KZ, and Mankoff DA, et al (2005). Progress and promising of FDG-PET imaging for cancer patient management and oncologic drug development. *Clin Cancer Res* 11, 2785.

Weber WA, Gatsonis CA, Moley PD, Hanna LG, Shields AF, Abele DR, Govindan R, Torigian DA, Karp JS, and Yu JQ, et al (2015). Repeatability of 18F-FDG PET/CT in advanced non–small cell lung cancer: prospective assessment in 2 multicenter trials. *J Nucl Med* 56, 1137.

Yankelevich TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessey FM, Huang W, and Kalpathy-Cramer J, et al (2016). Quantitative imaging in cancer clinical trials. *Clin Cancer Res* 22, 284.

Mankoff DA, O’ Sullivan F, Barlow WE, and Krohn KA (2007). Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy. *Acad Radiol* 14, 398–405. https://doi.org/10.1016/j.acra.2007.01.005.

Feber WA (2006). Positron emission tomography as an imaging biomarker. *J Clin Oncol* 24, 3282–3292. https://doi.org/10.1200/JCO.2006.06.6068.

Olivares A, Dührssen JHM, King A, Gottlieb E, and Halsey C (2015). Research into cancer metabolomics: towards a clinical morphospheres. *Semin Cell Dev Biol* 43, 52–64. https://doi.org/10.1016/j.semcdb.2015.09.008.

Akhurst T, MacManus M, and Hicks RJ (2015). Lung cancer. *PET Clin* 10, 147–158. https://doi.org/10.1016/j.petc.2014.12.002.

Shankar LK (2012). The clinical evaluation of novel imaging methods for cancer management. *Nat Rev Clin Oncol* 9, 738–744. https://doi.org/10.1038/nrclinonc.2012.186.

Henry NL and Hayes DF (2012). Cancer biomarkers. *Mol Oncol* 6, 140–146. https://doi.org/10.1016/j.molonc.2012.01.010.

Cheong H, Lu C, Lindsten T, and Thompson CB (2012). Therapeutic targets in cancer cell metabolism and autophagy. *Nat Biotechnol* 30, 671–678. https://doi.org/10.1038/nbt.2285.

Mankoff DA, Edmonds CE, Farwell MD, and Pryma DA (2016). Development of companion diagnostics. *Semin Nucl Med* 46, 47–56. https://doi.org/10.1053/j.senm.2015.09.002.

Pien HH, Fischman AJ, Thrall JH, and Sorensen AG (2005). Using imaging biomarkers to accelerate drug development and clinical trials. *Drug Discov Today* 10, 259–266. https://doi.org/10.1016/S1359-6446(04)03343-3.

Smith JJ, Sorensen AG, and Thrall JH (2003). Biomarkers in imaging: realizing radiology’s future. *Radiology* 227, 633–638. https://doi.org/10.1148/radiology.2273020518.

Dang CV, Hamaker M, Sun P, Le A, and Gao P (2011). Therapeutic targeting of cancer cell metabolism. *J Mol Med* 89, 205–212. https://doi.org/10.1007/s00109-011-0730-x.

Moghbel MC, Kostakoglu L, Zukotynski K, Chen DL, Nadel H, Niederkohr M, and Halsey C (2015). Research into cancer metabolomics: towards a clinical morphospheres. *Semin Nucl Med* 45, 744.

McShane LM and Hayes DF (2012). Publication of tumor marker research results: the necessity for complete and transparent reporting. *JAMA Oncol* 27, 643–646.

Dunnwald LK, Doott RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, and Schubert EK, et al (2011). PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. *Clin Cancer Res* 17, 2400.

Muiz M, O’Sullivan F, Mankoff DA, Doott RK, Pierce LA, Kurland BF, Linden HM, and Kinahan PE (2012). Quantitative assessment of PET imaging data in cancer imaging. *Magn Reson Imaging* 30, 1203.

Huang SC (2000). Anatomy of SUV. Standardized uptake value. *Nucl Med Biol* 27, 643–646.

McShane LM and Hayes DF (2012). Publication of tumor marker research results: the necessity for complete and transparent reporting. *J Clin Oncol* 30, 4223–4232. https://doi.org/10.1200/JCO.2012.42.6858.

Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, and Van den Abbeele A, et al (2006). I. National Cancer, Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. *J Nucl Med* 47, 1059.

Mankoff DA, Pryma DA, and Clark AS (2014). Making molecular imaging a clinical tool for precision oncology: a review. *JAMA Oncol* 10.1001/jamaoncol.2016.5084.

Dunnwald LK, Doott RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, Linden HM, Gadi VK, Kurland BF, and Schubert EK, et al (2011). PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. *Clin Cancer Res* 17, 2400.

Muiz M, O’Sullivan F, Mankoff DA, Doott RK, Pierce LA, Kurland BF, Linden HM, and Kinahan PE (2012). Quantitative assessment of PET imaging data in cancer imaging. *Magn Reson Imaging* 30, 1203.

Huang SC (2000). Anatomy of SUV. Standardized uptake value. *Nucl Med Biol* 27, 643–646.

McShane LM and Hayes DF (2012). Publication of tumor marker research results: the necessity for complete and transparent reporting. *J Clin Oncol* 30, 4223–4232. https://doi.org/10.1200/JCO.2012.42.6858.

Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, Larson S, Mankoff DA, Siegel BA, and Van den Abbeele A, et al (2006). I. National Cancer, Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. *J Nucl Med* 47, 1059.

Mankoff DA, Pryma DA, and Clark AS (2014). Making molecular imaging biomarkers for oncology clinical trials. *J Nucl Med* 55, 525–528. https://doi.org/10.2967/jnumed.113.126128.

Gottlieb E, Zhink Z, Fink JR, Muiz M, Hanna L, Greco E, Prah M, Schmida KM, Mintz A, and Kostakoglu L, et al (2016). ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed glioblastoma using 18F-FMISO PET and MRI. *Clin Cancer Res* 22, 5079.

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muiz M, Cormack J, Muiz JP, Pryma DA, and Specht JM, et al (2015). A phase II study of 3-deoxy-3-18F-fluorothymidine PET in the assessment of early response of breast cancer to neoadjuvant chemotherapy: results from ACRIN 6688. *J Nucl Med* 56, 1681.
Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, and Fitzgerald TJ (2009). Considerations for the use of imaging tools for phase II treatment trials in oncology. *Clin Cancer Res* **15**, 1891–1897. https://doi.org/10.1158/1078-0432.CCR-08-2030.

Coleman RE, Delbeke D, Guiberteau MJ, Conti PS, Royal HD, Weinreb JC, Siegel BA, Federle MF, Townsend DW, and Berland LL, et al (2005). Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. *J Nucl Med* **46**, 1225.

Lehman CD, DeMartini W, Anderson BO, and Edge SB (2009). Indications for breast MRI in the patient with newly diagnosed breast cancer. *J Natl Compr Canc Netw* **7**, 193–201.

Zierhut ML, Yen YF, Chen AP, Bok R, Albers MJ, Zhang V, Tropp J, Park I, Vigneron DB, and Kurhanewicz J, et al (2010). Kinetic modeling of hyperpolarized 13C1-pyruvate metabolism in normal rats and TRAMP mice. *J Magn Reson* **202**, 85.